Collectively, our results indicate that IGF2BP3 promotes HMGB1 stability by directly binding to HMGB1 mRNA through m6A modification in bladder cancer cells and suggest a potential role for IGF2BP3 in modulating the immune response in BLCA and its impact on immunotherapy efficacy. Here, HMGB1 is linked to bladder transitional cell carcinoma.